摘要
目的探讨纳米白蛋白结合型紫杉醇治疗晚期和复发子宫颈癌患者的效果及安全性。方法采用回顾性队列研究方法,选取延安大学附属医院2013年1月至2018年1月诊治的晚期、复发子宫颈癌患者52例作为研究对象,采用纳米白蛋白结合型紫杉醇联合顺铂方案治疗,分析疗效及不良反应发生情况。结果52例晚期、复发子宫颈癌患者总客观缓解率为67.3%(35/52),疾病控制率为88.5%(46/52),无进展生存期为(11.7±3.6)个月。接受过放疗者和距前次化疗时间>12个月者的客观缓解率分别高于未接受过放疗者和距前次化疗时间≤12个月者[76.9%(30/39)比46.2%(6/13),χ2=4.333,P=0.037;78.9%(15/19)比43.8%(7/16),χ2=4.609,P=0.032]。晚期、复发、是否接受过放疗、是否接受过化疗和距前次化疗时间对疾病控制率均无影响(均P>0.05)。接受过放疗者和距前次化疗时间>12个月高于者治疗后无进展生存期分别长于未接受过放疗者和距前次化疗时间≤12个月者[(13.0±4.4)个月比(8.7±2.9)个月,t=3.029,P=0.004;(12.8±3.1)个月比(9.6±4.0)个月,t=2.665,P=0.012]。不良反应中发生率较高的是骨髓抑制(82.7%,43/52)和胃肠道反应(65.4%,34/52),且Ⅲ~Ⅳ级不良反应中以骨髓抑制最多(20例)。结论纳米白蛋白结合型紫杉醇联合顺铂方案治疗晚期、复发子宫颈癌患者安全有效。
Objective To investigate the efficacy and safety of nano-particle albumin bound paclitaxel in the treatment of patients with advanced and relapsed cervical cancer.Methods A retrospective cohort study was conducted.Among the cervical cancer patients who were diagnosed and treated in Affiliated Hospital of Yan'an University from January 2013 to January 2018,52 advanced and relapsed cases were selected as the research objects.The chemotherapy protocol of nano-particle albumin bound paclitaxel and cisplatin was used,and the efficacy and toxicity of chemotherapy were analyzed.Results The total objective remission rate of 52 patients with advanced or relapsed cervical cancer was 67.3%(35/52),the disease control rate was 88.5%(46/52),and the progression-free survival time was(11.7±3.6)months.The objective remission rate in patients who had received radiotherapy and with a time interval of>12 months since their last chemotherapy was higher than that in patients who had not received radiotherapy and with a time interval of≤12 months since their last chemotherapy[76.9%(30/39)vs.46.2%(6/13),χ2=4.333,P=0.037;78.9%(15/19)vs.43.8%(7/16),χ2=4.609,P=0.032].Late stage,relapse,whether received radiotherapy,whether received chemotherapy and the time from the previous chemotherapy had no effect on the disease control rate(all P>0.05).The progression-free survival time in patients who underwent radiotherapy and with a time interval of>12 months since their last chemotherapy was longer than that in patients who had not received radiotherapy and with a time interval of≤12 months since their last chemotherapy[(13.0±4.4)months vs.(8.7±2.9)months,t=3.029,P=0.004;(12.8±3.1)months vs.(9.6±4.0)months,t=2.665,P=0.012].The highest incidence rates of adverse reactions were myelosuppression(82.7%,43/52)and gastrointestinal reaction(65.4%,34/52),and the most common gradeⅢ-Ⅳadverse reaction was myelosuppression(20 cases).Conclusion The efficacy and safety of nano-particle albumin bound paclitaxel combined with cisplatin in the treat
作者
魏建勋
李彦荣
呼改琴
王楠
Wei Jianxun;Li Yanrong;Hu Gaiqin;Wang Nan(Department of Gynecology and Obstetrics,Affiliated Hospital of Yan'an University,Yan'an 716000,China;Department of Gynecology and Obstetrics,the First Medical Center of PLA General Hospital,Beijing 100853,China)
出处
《肿瘤研究与临床》
CAS
2020年第5期331-334,共4页
Cancer Research and Clinic
基金
国家自然科学基金(81571411)。
关键词
宫颈肿瘤
药物疗法
联合
晚期
复发
白蛋白结合型紫杉醇
Uterine cervical neoplasms
Drug therapy
combination
Advanced
Recurrence
Albumin bound paclitaxel
